ImmuPharma (LON:IMM) Stock Price Down 15.3% - Here's Why

Key Points

• ImmuPharma plc shares fell by 15.3%, trading as low as GBX 14.50 during mid-day trading, marking a significant drop from its previous close of GBX 17.60.
• Trading volume surged to 30,500,184 shares, an increase of 263% compared to the average session volume, indicating heightened investor activity.
• The company reported a negative earnings per share (EPS) of GBX (0.38) for the quarter, with analysts predicting an EPS of -339.0000022 for the current fiscal year.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded down 15.3% during mid-day trading on Tuesday . The company traded as low as GBX 14.50 ($0.20) and last traded at GBX 14.90 ($0.20). 30,500,184 shares changed hands during trading, an increase of 263% from the average session volume of 8,394,409 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Price Performance

The stock's fifty day moving average price is GBX 3.68 and its 200-day moving average price is GBX 3.09. The firm has a market cap of £74.46 million, a price-to-earnings ratio of -1,674.16 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.